{
    "clinical_study": {
        "@rank": "90916", 
        "brief_summary": {
            "textblock": "To determine the safety and efficacy of two doses of interferon alfa-2a ( IFN alfa-2a ) in\n      combination with zidovudine ( AZT )/zalcitabine ( ddC ) versus AZT/ddC only in patients with\n      HIV infection and CD4 count < 400 cells/mm3.\n\n      AZT and ddC inhibit HIV by acting as reverse transcriptase chain terminators, while IFN\n      alfa-2a inhibits translation of viral proteins. Combining agents that act at different sites\n      of viral replication may improve HIV inhibition and produce more effective and sustained\n      anti-HIV effects."
        }, 
        "brief_title": "A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3", 
        "completion_date": {
            "#text": "February 1995", 
            "@type": "Actual"
        }, 
        "condition": "HIV Infections", 
        "condition_browse": {
            "mesh_term": [
                "HIV Infections", 
                "Acquired Immunodeficiency Syndrome"
            ]
        }, 
        "detailed_description": {
            "textblock": "AZT and ddC inhibit HIV by acting as reverse transcriptase chain terminators, while IFN\n      alfa-2a inhibits translation of viral proteins. Combining agents that act at different sites\n      of viral replication may improve HIV inhibition and produce more effective and sustained\n      anti-HIV effects.\n\n      Patients are randomly assigned to one of three treatment arms to receive AZT/ddC alone or\n      combined with one of two doses of IFN alfa-2a. Treatment continues for up to 12 months after\n      enrollment of the last patient. Patients are followed at 2, 4, and 8 weeks and every 8 weeks\n      thereafter. Mean duration of follow-up is expected to be 13 months."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria\n\n        Concurrent Medication:\n\n        Allowed:\n\n          -  Isoniazid for < grade 2 peripheral neuropathy (if patient is also taking 50 mg/day\n             pyridoxine).\n\n          -  Phenytoin for < grade 2 peripheral neuropathy.\n\n          -  A 21-day course of adjuvant systemic corticosteroid therapy for moderate to severe\n             Pneumocystis carinii pneumonia (PCP).\n\n          -  Chemoprophylaxis for PCP, candidiasis, herpes simplex infection (up to 1 g acyclovir\n             daily), and Mycobacterium tuberculosis.\n\n        Patients must have:\n\n          -  HIV infection.\n\n          -  CD4 count < 400 cells/mm3 within 30 days prior to study entry.\n\n        NOTE:\n\n          -  Minimal Kaposi's sarcoma is allowed.\n\n        Exclusion Criteria\n\n        Co-existing Condition:\n\n        Patients with the following symptoms and conditions are excluded:\n\n          -  Active opportunistic infection requiring acute therapy.\n\n          -  Need for maintenance therapy for cytomegalovirus infection, toxoplasmic encephalitis,\n             or mycobacterial infection.\n\n          -  Malignancy (other than minimal Kaposi's sarcoma) requiring therapy.\n\n          -  Grade 2 or worse peripheral neuropathy.\n\n        Concurrent Medication:\n\n        Excluded:\n\n          -  Other antiretroviral drugs, biologic response modifiers, cytotoxic chemotherapy, or\n             investigational drugs (unless approved by the protocol chairs).\n\n          -  Recombinant erythropoietin, G-CSF, or GM-CSF.\n\n          -  Drugs that cause peripheral neuropathy, e.g., gold, hydralazine, nitrofurantoin,\n             vincristine, cisplatin, disulfiram, and diethyldithiocarbamate (unless approved by\n             the protocol chairs).\n\n        Concurrent Treatment:\n\n        Excluded:\n\n          -  Radiation therapy (unless approved by the protocol chairs).\n\n        Patients with the following prior conditions are excluded:\n\n          -  History of intolerance to AZT at 600 mg/day or less.\n\n          -  Unexplained temperature of 38.5 degrees C persisting for 14 days or longer.\n\n          -  Unexplained, chronic diarrhea defined as 3 or more stools per day persisting for 14\n             days or longer.\n\n        Prior Medication:\n\n        Excluded:\n\n          -  Acute therapy for opportunistic infection within 14 days prior to study entry.\n\n          -  Prior ddC, ddI, or IFN alfa-2a.\n\n        Active substance abuse."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": "60", 
        "firstreceived_date": "November 2, 1999", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT00000754", 
            "org_study_id": "ACTG 197", 
            "secondary_id": "11173"
        }, 
        "intervention": [
            {
                "intervention_name": "Interferon alfa-2a", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zidovudine", 
                "intervention_type": "Drug"
            }, 
            {
                "intervention_name": "Zalcitabine", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Interferon-alpha", 
                "Interferon Alfa-2a", 
                "Zalcitabine", 
                "Interferons", 
                "Zidovudine"
            ]
        }, 
        "keyword": [
            "Zalcitabine", 
            "Acquired Immunodeficiency Syndrome", 
            "AIDS-Related Complex", 
            "Zidovudine", 
            "Interferon-alpha"
        ], 
        "lastchanged_date": "March 28, 2012", 
        "link": [
            {
                "description": "Click here for more information about Zidovudine", 
                "url": "http://aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=4"
            }, 
            {
                "description": "Click here for more information about Zalcitabine", 
                "url": "http://aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=15"
            }, 
            {
                "description": "Click here for more information about Interferon alfa-2a", 
                "url": "http://aidsinfo.nih.gov/DrugsNew/DrugDetailNT.aspx?MenuItem=Drugs&Search=On&int_id=34"
            }
        ], 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Birmingham", 
                        "country": "United States", 
                        "state": "Alabama", 
                        "zip": "35294"
                    }, 
                    "name": "Alabama Therapeutics CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "La Jolla", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "Ucsd, Avrc Crs"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Diego", 
                        "country": "United States", 
                        "state": "California"
                    }, 
                    "name": "UCSD Maternal, Child, and Adolescent HIV CRS"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Miami", 
                        "country": "United States", 
                        "state": "Florida"
                    }, 
                    "name": "Univ. of Miami AIDS CRS"
                }
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "official_title": "A Randomized Phase II Study of Two Doses of Interferon Alfa-2a (IFN Alfa-2a) in Combination With Zidovudine (AZT) and Dideoxycytidine (ddC) Versus AZT and ddC Only in Patients With HIV Infection and Less Than 400 CD4 Cells/mm3", 
        "overall_official": [
            {
                "last_name": "Fischl MA", 
                "role": "Study Chair"
            }, 
            {
                "last_name": "Richman DD", 
                "role": "Study Chair"
            }
        ], 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "Unspecified"
        }, 
        "phase": "Phase 2", 
        "reference": {
            "PMID": "9402071", 
            "citation": "Fischl MA, Richman DD, Saag M, Meng TC, Squires KE, Holden-Wiltse J, Meehan PM. Safety and antiviral activity of combination therapy with zidovudine, zalcitabine, and two doses of interferon-alpha2a in patients with HIV. AIDS Clinical Trials Group Study 197. J Acquir Immune Defic Syndr Hum Retrovirol. 1997 Dec 1;16(4):247-53."
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT00000754"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "source": "National Institute of Allergy and Infectious Diseases (NIAID)", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Hoffmann-La Roche", 
                    "agency_class": "Industry"
                }, 
                {
                    "agency": "Glaxo Wellcome", 
                    "agency_class": "Industry"
                }
            ], 
            "lead_sponsor": {
                "agency": "National Institute of Allergy and Infectious Diseases (NIAID)", 
                "agency_class": "NIH"
            }
        }, 
        "study_design": "Endpoint Classification: Safety Study, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2012"
    }, 
    "geocoordinates": {
        "Alabama Therapeutics CRS": "33.521 -86.802", 
        "UCSD Maternal, Child, and Adolescent HIV CRS": "32.715 -117.157", 
        "Ucsd, Avrc Crs": "32.839 -117.277", 
        "Univ. of Miami AIDS CRS": "25.789 -80.226"
    }
}